Literature DB >> 8752909

Chemical denaturation and modification of ovalbumin alters its dependence on ubiquitin conjugation for class I antigen presentation.

M T Michalek1, E P Grant, K L Rock.   

Abstract

Class I presentation of microinjected native OVA by a temperature-sensitive ubiquitin conjugation mutant, ts85, but not wild-type murine cells, was markedly inhibited following incubation at a nonpermissive temperature. In contrast, the nonpermissive temperature did not affect class I presentation of a minimal OVA peptide expressed in the cytosol. Therefore, these results provide a second example in which a temperature sensitive mutation in the ubiquitin conjugation pathway inhibits MHC class I presentation of native OVA. Surprisingly, incubation at the nonpermissive temperature did not inhibit class I presentation of chemically denatured and alkylated OVA microinjected into the cytosol of mutant cells. Similarly, the presentation of endogenously synthesized OVA (which is expressed from a recombinant vaccinia virus and, presumably, is misfolded in the cytosol) was also not inhibited in both mutant cell lines. Methylation of the lysine groups in denatured OVA, which blocks ubiquitin conjugation, reduced but did not eliminate the presentation of denatured OVA, providing evidence for both ubiquitin-dependent and ubiquitin-independent pathways for class I presentation. In contrast, a proteasome inhibitor blocked class I presentation of all forms of OVA, while a control peptide aldehyde was not inhibitory. These results indicate that modification of the structure of a protein can influence its requirements for ubiquitin conjugation for efficient class I presentation, with the key alteration possibly being the loss of proper conformation. However, regardless of the form of the Ag, the proteasome appears to be required for generating peptides from both endogenously synthesized and microinjected OVA for class I presentation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8752909

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

2.  26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide.

Authors:  P Cascio; C Hilton; A F Kisselev; K L Rock; A L Goldberg
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

3.  Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein.

Authors:  Robert F Kalejta; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

4.  DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction.

Authors:  F Rodriguez; J Zhang; J L Whitton
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Varied Role of Ubiquitylation in Generating MHC Class I Peptide Ligands.

Authors:  Jiajie Wei; Damien Zanker; Anthony R Di Carluccio; Margery G Smelkinson; Kazuyo Takeda; Mina O Seedhom; Devin Dersh; James S Gibbs; Ning Yang; Ajit Jadhav; Weisan Chen; Jonathan W Yewdell
Journal:  J Immunol       Date:  2017-03-31       Impact factor: 5.422

6.  Identification of arginine- and lysine-methylation in the proteome of Saccharomyces cerevisiae and its functional implications.

Authors:  Chi Nam Ignatius Pang; Elisabeth Gasteiger; Marc R Wilkins
Journal:  BMC Genomics       Date:  2010-02-05       Impact factor: 3.969

7.  Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.

Authors:  Gary C Pien; Etiena Basner-Tschakarjan; Daniel J Hui; Ashley N Mentlik; Jonathan D Finn; Nicole C Hasbrouck; Shangzhen Zhou; Samuel L Murphy; Marcela V Maus; Federico Mingozzi; Jordan S Orange; Katherine A High
Journal:  J Clin Invest       Date:  2009-05-11       Impact factor: 14.808

Review 8.  Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems--role in ageing and disease.

Authors:  Paul J Thornalley
Journal:  Drug Metabol Drug Interact       Date:  2008

9.  COOH-terminal truncations promote proteasome-dependent degradation of mature cystic fibrosis transmembrane conductance regulator from post-Golgi compartments.

Authors:  M Benharouga; M Haardt; N Kartner; G L Lukacs
Journal:  J Cell Biol       Date:  2001-05-28       Impact factor: 10.539

10.  Fates of retroviral core components during unrestricted and TRIM5-restricted infection.

Authors:  Sebla B Kutluay; David Perez-Caballero; Paul D Bieniasz
Journal:  PLoS Pathog       Date:  2013-03-07       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.